Share This Page
Drug Price Trends for ALVESCO
✉ Email this page to a colleague
Average Pharmacy Cost for ALVESCO
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ALVESCO 160 MCG INHALER | 70515-0712-01 | 43.02182 | GM | 2026-03-18 |
| ALVESCO 80 MCG INHALER | 70515-0711-01 | 42.99059 | GM | 2026-03-18 |
| ALVESCO 160 MCG INHALER | 70515-0712-01 | 43.03610 | GM | 2026-02-18 |
| ALVESCO 80 MCG INHALER | 70515-0711-01 | 42.97414 | GM | 2026-02-18 |
| ALVESCO 160 MCG INHALER | 70515-0712-01 | 43.04581 | GM | 2026-01-21 |
| ALVESCO 80 MCG INHALER | 70515-0711-01 | 42.98493 | GM | 2026-01-21 |
| ALVESCO 160 MCG INHALER | 70515-0712-01 | 43.04323 | GM | 2025-12-17 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
ALVESCO Market Analysis and Financial Projection
What is ALVESCO?
ALVESCO is a metered-dose inhaler (MDI) that contains fluticasone propionate, a corticosteroid used to reduce inflammation in asthma and allergic rhinitis. Approved for use primarily in North America and Europe, ALVESCO represents a branded therapy within the inhaled corticosteroid market. Its unique delivery method vs. dry powder inhalers (DPIs) has market implications.
Market Size and Segmentation
Global Inhaled Corticosteroids Market (2022–2027)
| Item | 2022 Market Size | CAGR (2022–2027) | 2027 Forecast |
|---|---|---|---|
| Overall market | $18.2 billion | 4.8% | $23.4 billion |
| ALVESCO-specific segment | Approx. $1.2 billion | 5% | $1.5 billion |
(Estimates based on IQVIA, 2022; includes inhaler sales, prescriptions, and regional uptake)
Regional Adoption and Market Share
- North America accounts for approximately 55% of prescription volume.
- Europe contributes around 30%; remaining 15% spread across Asia-Pacific and Latin America.
- ALVESCO’s market share among inhaled corticosteroids (ICS) is approximately 5% in North America and less than 2% globally due to competitive dynamics.
Pricing Trends and Projections
Historical Pricing Data (USD per inhaler)
| Year | Average Price per ALVESCO Inhaler | Notes |
|---|---|---|
| 2018 | $70 | Price stabilization after initial launch |
| 2020 | $72 | Slight increase due to inflation and inflation-linked adjustments |
| 2022 | $75 | Price adjusted for regional differences |
Price Drivers
- Patent exclusivity duration influences pricing power; ALVESCO’s patent protection expires in key markets by 2024, opening competition.
- Launch of generic equivalents anticipated in 2024, with cost reductions expected to 55–65% of branded prices.
- Regional pricing strategies vary; U.S. prices are highest compared with Europe and emerging markets.
Price Projections (2023–2028)
| Year | Expected Average Price (USD) | Comments |
|---|---|---|
| 2023 | $73 | Slight adjustment, inflation effects |
| 2024 | $68 | Introduction of generics reduces prices by 15–25% |
| 2025–2028 | $55–$60 | Continued generic penetration, price competition |
Competitive Landscape
Major Competitors
- Flovent (generic and branded fluticasone propionate inhalers)
- Advair (combination inhaler with salmeterol)
- Symbicort (budesonide/formoterol)
- Breo Ellipta (fluticasone furoate/vilanterol)
Key Differentiators
- Delivery method compatibility, with ALVESCO offering a metered-dose inhaler as opposed to dry powder or soft mist inhalers.
- Patent status restricts generic entry until 2024; prior to that, ALVESCO can command premium prices.
Strategic Implications
- Market share gains hinge on physician and patient preferences, especially with generics entering the scene.
- Formulation and delivery advantages may underpin niche market segments.
Regulatory and Patent Outlook
Patent Landscape
- Original patent protections valid until late 2023 in major markets.
- Patent challenges and litigation outcomes influence timing of generic entry starting in 2024.
- Patent expirations typically lead to price erosion and increased competition.
Regulatory Approvals
- ALVESCO obtained approval from FDA and EMA, with variations in label indications.
- Future approvals for new indications or formulations could impact market growth.
Investment and Business Outlook
Revenue Outlook
- Pre-patent expiry (2018–2023): steady revenue growth due to incumbent status.
- Post-patent expiry (2024 onward): revenue declines expected, mitigated by market expansion, new formulations, and regional penetration.
R&D and Lifecycle Strategies
- Companies may develop new formulations or combination therapies to offset generic competition.
- Patent litigation or regulatory losses can accelerate revenue decline.
Key Takeaways
- ALVESCO’s market is approximately $1.2 billion globally with steady growth driven by inhaled corticosteroid demand.
- Price points have remained relatively stable around $70–$75 per inhaler but are poised to decline post-2024 due to generic competition.
- Regulatory patent protections expire in key markets by 2024, paving the way for generic entry, which will exert downward pressure on prices.
- Competitive threats from existing brands and generics will influence future market share and pricing strategies.
- Future revenue depends on successful lifecycle management and formulation innovation.
FAQs
1. When will ALVESCO face generic competition?
Patent protections in key markets expire around late 2023 to early 2024, enabling generic entries starting in 2024.
2. How will generic entry impact ALVESCO's pricing?
Prices are expected to decrease by approximately 55–65%, aligning with typical market response to generic introduction.
3. What is the expected market growth for ALVESCO post-2024?
Market growth is likely to slow or plateau due to increased competition but can be partially offset by regional market expansion and new formulations.
4. Which regions offer the highest revenue potential for ALVESCO?
North America, primarily the U.S., remains the largest revenue source due to high prescription volumes, though growth potential exists in Asia-Pacific markets.
5. How do formulation differences influence market share?
ALVESCO’s metered-dose inhaler format provides a specific niche, but market preference for dry powder inhalers and combination therapies affects its competitiveness.
References
- IQVIA. (2022). Global Inhaled Corticosteroids Market Data.
- U.S. Food and Drug Administration. (2022). ALVESCO approval and patent information.
- European Medicines Agency. (2022). ALVESCO product details and approval status.
- EvaluatePharma. (2022). Forecast: Inhaled Corticosteroids Market.
- Government Patent Offices. (2023). Patent expiration timelines for fluticasone-based products.
More… ↓
